| Literature DB >> 26457009 |
Melissa Latorre1, Suneeta Krishnareddy1, Daniel E Freedberg1.
Abstract
The intestinal microbiome is emerging as a crucial mediator between external insults and systemic infections. New research suggests that our intestinal microorganisms contribute to critical illness and the development of non-gastrointestinal infectious diseases. Common pathways include a loss of fecal intestinal bacterial diversity and a disproportionate increase in toxogenic bacterial species. Therapeutic interventions targeting the microbiome - primarily probiotics - have yielded limited results to date. However, knowledge in this area is rapidly expanding and microbiome-based therapy such as short-chain fatty acids may eventually become a standard strategy for preventing systemic infections in the context of critical illness.Entities:
Keywords: Clostridium difficile; Critical illness; Gut; Microbiome; Probiotics; Short-chain fatty acids
Mesh:
Substances:
Year: 2015 PMID: 26457009 PMCID: PMC4588071 DOI: 10.3748/wjg.v21.i37.10487
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742